Immunovant, Inc. · NASDAQ:IMVT

Immunovant — Investor Day (September 2021)

7 slides from Immunovant's investor day presentation, Sep 27, 2021

  1. Slide 1: Roivant R&D Day Investor Presentation

    For Investor Audiences Only Roivant R&D Day Investor Presentation September 28, 2021 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    For Investor Audiences Only Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,”

  3. Slide 3: Rethinking possibilities in autoimmune disease

    For Investor Audiences Only Rethinking possibilities in autoimmune disease 3 Love Trailblazing All Voices Bolder Faster Our vision: Normal lives for people with autoimmune diseases

  4. Slide 4: Anti-FcRn Market: Potential therapeutic benefit across wide range of indications

    For Investor Audiences Only 4 Anti-FcRn Market: Potential therapeutic benefit across wide range of indications Fifteen indications announced by at least one anti-FcRn program ENDOCRINOLOGY Thyroid eye disease RHEUMATOLOGY Primary Sjögrens Syndrome Lupus Nephritis Systemic lupus erythematosus Rheumat

  5. Slide 5: Despite available treatment options, people with Myasthenia Gravis report unmet needs

    For Investor Audiences Only 5Source: Analysis – Social Media Review MG n=975 / Qualitative research – MG patient journey n=28 / MG Patient Advisory Council n=6 / MG Patient Quantitative Survey (n=50) • Even well controlled patients report lifestyle accommodations • Anxiety around response and durati

  6. Slide 6: Dosing approach preferences

    For Investor Audiences Only Dosing approach preferences 6 Source: Analysis – MG Patient Quantitative Survey (n=50) 94% of respondents with Myasthenia Gravis prefer chronic versus intermittent dosing Patient Survey Feedback: Preferred Treatment Approach 94% 6%I want to stay on my MG treatment, even w

  7. Slide 7: Batoclimab's differentiated attributes provide a unique opportunity to address unmet needs

    For Investor Audiences Only Batoclimab’s (IMVT-1401) differentiated attributes provide a unique opportunity to address patients’ unmet needs 7 Subcutaneous route of administration: Designed and developed for simple subcutaneous injection to provide human-centric, give and go dosing experience Signif

Immunovant — Investor Day (September 2021) on 6ix